Nicotine
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Nicotine
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
Smoking remains the leading cause of preventable disease and death in the US, killing more than 480,000 Americans each year. Smoking cessation is possible and can save lives. This session will discuss tobacco use in different populations, GLP-1 use for smoking cessation, comparative effectiveness of treatment models, and more, to provide a comprehensive overview of the state of the art of treatment for nicotine use disorder.
This session is comprised of 4 presentations and a panel that dive deep into different aspects of the overall topic.
- Adaptive Trials for Tobacco Cessation
This session will review clinical trials testing the development or comparative effectiveness of adaptive tobacco cessation treatment models which adapt individual cessation treatment based on user response. The session will further explore the strengths and limitations of different trial designs and assess the generalizability of adaptive treatment research findings for use in clinical practice. - GLP-1 Agonists for the Treatment of Nicotine Dependence and Post-Cessation Weight Management: The Skinny on Novel Anti-Obesity Medications
Despite tremendous health benefits, smoking cessation leads to an increased consumption of highly palatable foods. As a result, the majority of former smokers gain weight after quitting. Post-cessation weight gain (PCWG) can decrease smoking cessation motivation and success, and it can have detrimental effects on metabolic health in those who do achieve abstinence. This presentation will focus on the potential utility of glucagon-like peptide 1 receptor agonists (GLP1-RA) for addressing tobacco smoking and post-cessation weight management. The author will discuss the overall state of the science on targeting GLP-1Rs to reduce tobacco smoking and PCWG, with the primary focus on the completed and ongoing clinical trials conducted by our group. Directions for future clinical research will be provided. - Tobacco Use among Older Adults: A Forgotten Population
The number of adults 65 years and older is projected to nearly double between 2012 and 2050, prompting global efforts to address the inevitable challenges of this population shift. Of concern is the parallel observation that tobacco smoking prevalence in the US and other countries has declined considerably for all age groups except for those 65 and older. Given these trends, it is likely that the absolute number of older adults who smoke will increase in the coming years. This presentation will explore these trends and address older adults' interest in quitting and cessation rates. The presentation will also expand on the recently published ASAM Criteria (4th Ed) chapter on tobacco use, focusing on older adults and harm reduction approaches. - Novel and Emerging Interventions for Patients Unwilling to Quit
Smoking tobacco cigarettes is associated with premature mortality. Quitting smoking can help people gain between 3 to 10 Quality Adjusted Life Years (QALYs). However, even the best evidence-based treatments have low absolute quit rates. Repeated attempts are associated with greater success and should be encouraged. Unfortunately, some populations such as those with concurrent addictions and or mental illness are "treatment resistant". This session will present emerging evidence on novel and new interventions (e.g. brain stimulation) that could help them stop smoking cigarettes for good. In addition, this session will invite attendees to appraise the evidence for off-label use of existing treatments including combination, higher doses, extended treatment, and lower risk nicotine use guidelines.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Peter Selby
MBBS, CCFP, FCFP, DFASAM
Dr. Peter Selby is a Senior Medical Consultant and Clinician Scientist at the Centre for Addiction and Mental Health (CAMH). He is the Vice-Chair, of Research, and Giblon Professor in Family Medicine Research, a University Named Professorship at the University of Toronto. He is also the Director of the Mental Health and Addictions Division in the Department of Family and Community Medicine, University of Toronto. His research focuses on innovative methods to understand and treat addictive behaviors and their comorbidities. He also uses technology to combine clinical medicine and public health methods to scale up and test health interventions.
He has received grant funding totaling over 100 million dollars from CIHR, NIH, and the Ministry of Health and has published >150 peer-reviewed publications. He has published 6 books (including 5 edited), is the author of 31 book chapters, and has 38 research reports prepared for the government. He is the Chair of the Medical Education Council for the American Society of Addiction Medicine. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators, and medical students. The use of innovative methods to communicate messages makes Dr. Selby a sought-after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change at individual and system levels.
Does Disclose - Johnson and Johnson, Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Pfizer, Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment
Luba Yammine
PhD, APRN, FNP-C
Dr. Yammine,is a clinician and research scientist specializing in the treatment of substance use disorders, including tobacco, alcohol and OUD. She is a provider of medication-assisted treatment and authorized to prescribe buprenorphine to treat OUD. She is also a nationally certified Tobacco Treatment Specialist. Her treatment approach is holistic and integrates services to address addiction along with co-occurring mental and medical issues into the comprehensive care of the individual. As a researcher, Yammine is the Primary Investigator of a CCTS exenatide as a potential treatment for smoking cessation. She is also a Primary/ Co-Investigator on several Department of Defense funded projects that focus on treatments for Veterans with substance use disorders. She completed her undergraduate studies in nursing at Texas Woman’s University and Master’s and Doctoral studies at the University of Texas Health Science Center at Houston. She went on to complete postdoctoral training in addiction research at Baylor College of Medicine/Michael E. DeBakey VA Medical Center.
Gina R. Kruse, MD, MS, MPH
Associate Professor
University of Colorado School of Medicine
Dr. Gina Kruse is a physician researcher in the Division of General Internal Medicine at the University of Colorado School of Medicine. She trained in internal medicine and primary care at Massachusetts General Hospital, completed a Harvard Medical School General Internal Medicine research fellowship, earned her MPH in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health followed by a post-doctoral fellowship in Cancer Prevention from the Harvard T.H. Chan School of Public Health Department of Social and Behavioral Sciences. Dr. Kruse’s research uses clinical trials, observational research, and mixed methods to test interventions and examine implementation strategies to improve the delivery of preventive services with a focus on improving tobacco cessation treatment in healthcare settings in the US and internationally.
No relevant financial disclosures
Bethea (Annie) Kleykamp, PhD, MA
Assistant Professor
University of Maryland School of Medicine
Bethea (Annie) Kleykamp, MA, PhD, is an Assistant Professor at the University of Maryland School of Medicine and the Director of Research and Evaluation at the Maryland Addiction Consultation Service. Dr. Kleykamp’s graduate training was in cognitive psychopharmacology, and she completed postdoctoral fellowships in behavioral pharmacology and nicotine psychopharmacology. Dr. Kleykamp’s research focuses on the impact of substance use and related policies on the growing older adult population and the importance of harm reduction. In 2011, Dr. Kleykamp chose a career trajectory off the beaten path in science writing and health policy, including positions that spanned the non-profit, for-profit, and public healthcare sectors. During this time, she also created a science writing business, BAK and Associates, which provides expert guidance on science communication and systematic review development. Despite being outside the traditional academic path, she has maintained her scholarly productivity, authoring over 75 systematic reviews, peer-reviewed publications, and popular press articles on aging, nicotine/tobacco use, opioids, chronic pain, and clinical trial design. Dr. Kleykamp is currently running a pilot trial of e-cigarettes as a harm reduction tool among older adults who smoke tobacco and are in outpatient treatment for opioid use disorder.
No relevant financial disclosures
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 2.00 Credit(s)
- Nurses & NPs: 2.00 Nursing Contact Hour(s)
- Pharmacology Hour(s): .5 Hour(s)
- PAs: 2.00 Credit(s)
- Pharmacists: 2.00 Credit(s)
- Interprofessional Continuing Education: 2.00 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist Survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab. For any questions or concerns, please e-mail Education@ASAM.org
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 2.00 Lifelong Learning
- ABIM MOC Points: 2.00 Medical Knowledge
- ABP MOC: 2.00 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 2.00 Accredited CME | 2.00 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked